Humanized disulfide‐stabilized diabody against fibroblast growth factor‐2 inhibits PD‐L1 expression and epithelial‐mesenchymal transition in hepatoma cells through STAT3
IUBMB Life · 2023
DOI: 10.1002/iub.2766 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, 2023. Verfasst von Huamin Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Biology, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Fibroblast growth factor 2 (FGF2) plays an important role in tumor angiogenesis. Humanized disulfide‐stable double‐chain antibody against fibroblast growth factor‐2 (anti‐FGF2 ds‐Diabody) is a small molecule antibody with good tissue permeability and low immunogenicity, which has potential in tumor‐targeted therapy. This study intended to investigate the effect of anti‐FGF2 ds‐Diabody on the migration and expression of programmed death‐ligand1 (PD‐L1) in hepatocellular carcinoma (HCC) cells. The anti‐FGF2 ds‐Diabody was expressed under methanol induction and purified with Ni 2+ ‐affinity chromatography. Anti‐FGF2 ds‐Diabody significantly inhibited cell viability and proliferation in SK‐Hep1 and HepG2 cells as confirmed by CCK‐8 assays and colony formation assays. Western blot assays indicated that the proliferation of SK‐Hep1 and HepG2 cells was inhibited by anti‐FGF2 ds‐Diabody through inhibiting the phosphorylation activation of AKT and MAPK. The results of transwell and western blot assays showed that the migration and invasion of SK‐Hep1 and HepG2 cells were suppressed by anti‐FGF2 ds‐Diabody by affecting the epithelial‐mesenchymal transition (EMT) process. Meanwhile, anti‐FGF2 ds‐Diabody inhibited the expression of PD‐L1, and STAT3 participated in this process. Analysis of RT‐PCR and Western blot suggested that fibroblast growth factor receptor 4 inhibitor 1 (FGFR4‐IN‐1) suppressed the expression of PD‐L1, while STAT3 overexpression reversed this inhibitory effect. In addition, overexpression of STAT3 promoted migration and invasion and restored the suppressive effect of anti‐FGF2 ds‐Diabody on EMT. In conclusion, anti‐FGF2 ds‐Diabody could inhibit the expression of PD‐L1 and EMT of hepatoma cells through FGF2/FGFR4/STAT3 axis. These results suggested that anti‐FGF2 ds‐Diabody has potential clinical application in inhibiting metastasis and immune escape of hepatocellular carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Province Engineering Research Center for Antibody Drug and Immunoassay, Department of Biology, Jinan University, Guangzhou, China.
ORCID-Profile: Xinran Song, Ning Deng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sun, H., Song, X., Li, C., Li, Q., Liu, S., & Deng, N. (2023). Humanized disulfide‐stabilized diabody against fibroblast growth factor‐2 inhibits PD‐L1 expression and epithelial‐mesenchymal transition in hepatoma cells through STAT3. IUBMB Life. https://doi.org/10.1002/iub.2766
Vancouver
Sun H, Song X, Li C, Li Q, Liu S, Deng N. Humanized disulfide‐stabilized diabody against fibroblast growth factor‐2 inhibits PD‐L1 expression and epithelial‐mesenchymal transition in hepatoma cells through STAT3. IUBMB Life. 2023. doi:10.1002/iub.2766
BibTeX
@article{Sun2023,
author = {Sun, Huamin and Song, Xinran and Li, Cunjie and Li, Qing and Liu, Shifeng and Deng, Ning},
title = {Humanized disulfide‐stabilized diabody against fibroblast growth factor‐2 inhibits PD‐L1 expression and epithelial‐mesenchymal transition in hepatoma cells through STAT3},
journal = {IUBMB Life},
year = {2023},
doi = {10.1002/iub.2766}
}
EUVIMED